Repligen (NASDAQ:RGEN) Posts Earnings Results, Beats Expectations By $0.05 EPS

Repligen (NASDAQ:RGEN) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05, FiscalAI reports. The business had revenue of $197.91 million during the quarter, compared to analysts’ expectations of $192.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.66%.

Repligen Stock Down 0.2%

RGEN opened at $135.40 on Tuesday. The firm has a market cap of $7.62 billion, a P/E ratio of 6,773.39, a price-to-earnings-growth ratio of 2.48 and a beta of 1.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The business has a 50 day moving average price of $156.30 and a 200 day moving average price of $146.71. Repligen has a twelve month low of $102.96 and a twelve month high of $175.77.

Insider Buying and Selling

In other news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director owned 91,821 shares of the company’s stock, valued at $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. United Capital Financial Advisors LLC bought a new position in Repligen in the 3rd quarter worth $368,387,000. Opti Capital Management LP acquired a new stake in shares of Repligen in the fourth quarter valued at about $2,399,209,000. Price T Rowe Associates Inc. MD increased its stake in shares of Repligen by 31.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after purchasing an additional 1,091,683 shares during the period. RTW Investments LP acquired a new position in shares of Repligen during the 4th quarter worth about $174,347,000. Finally, Balyasny Asset Management L.P. boosted its stake in Repligen by 390.6% during the 3rd quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company’s stock valued at $102,557,000 after purchasing an additional 610,837 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on RGEN shares. Wells Fargo & Company increased their price objective on Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 17th. Barclays boosted their price target on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Jefferies Financial Group set a $160.00 price objective on Repligen and gave the stock a “hold” rating in a report on Tuesday, October 28th. Finally, Canaccord Genuity Group lifted their target price on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $177.92.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.